\n

Presentation

\nSabitar 24/26: Each film coated tablet contains Sacubitril Valsartan Sodium Hemipentahydrate INN equivalent to Sacubitril 24 mg and Valsartan 26 mg. \nSabitar 49/51: Each film coated tablet contains Sacubitril Valsartan Sodium Hemipentahydrate INN equivalent to Sacubitril 49 mg and Valsartan 51 mg. \nSabitar 97/103: Each film coated tablet contains Sacubitril Valsartan Sodium Hemipentahydrate INN equivalent to Sacubitril 97 mg and Valsartan 103 mg. \n \n

\n

Description

\nSacubitril, a neprilysin inhibitor that inhibits neprilysin (neutral endopeptidase; NEP) via active metabolite of the prodrug sacubitril. Valsartan, a angiotensin receptor blocker that blocks the angiotensin II type-1 (AT1) receptor. The cardiovascular and renal effects of Sacubitril/Valsartan in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides by the active metabolite of sacubitril and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release. \n \n

\n

Indications

\nSacubitril/Valsartan combination is indicated to \n \n? Reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. \n \nSacubitril/Valsartan is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB. \n \n

\n

Dosage & Administration

\n? The recommended starting dose of Sacubitril/Valsartan is 49/51 mg twice-daily. Double the dose of Sacubitril/Valsartan after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice-daily, as tolerated by the patient. \n? Reduce the starting dose to 24/26 mg twice-daily for: \n- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents \n- Patients with severe renal impairment \n- Patients with moderate hepatic impairment \nDouble the dose of Sacubitril/Valsartan every 2 to 4 weeks to the target maintenance dose of 97/103 mg twice-daily, as tolerated by the patient \n \n

\n

Side Effects

\nThe most common side effects are low blood pressure, high potassium, cough, dizziness, and kidney problems. It may cause some serious side-effects like angioedema (that may cause trouble in breath and death) and Hyperkalemia. \n \n

\n

Precautions

\nSigns and symptoms of angioedema and hypotension should be observed \n? Renal function and potassium level should be monitored in susceptible patients \nUse in specific populations: \nPregnancy: Sacubitril/Valsartan can cause fetal harm when administered to a pregnant woman \nLactation: Drug should be discontinued during lactation \nPediatric use: Safety and effectiveness in pediatric patients have not been established \nGeriatric use: No relevant pharmacokinetic differences have been observed in elderly (?65 years) or very elderly (?75 years) patients compared to the overall population \nHepatic impairment: Use not recommended \n \n

\n

Drug Interaction

\nDual blockade of the renin-angiotensin system: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided \nPotassium-sparing diuretics: Serum potassium level may be increased \nNSAIDs: Risk of renal impairment may be increased \nLithium: Increased risk of lithium toxicity \n \n

\n

Over Dose

\nLimited data are available with regard to overdosage in human subjects with Sacubitril and Valsartan. In healthy volunteers, a single dose of 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. \nHypotension is the most likely result of overdosage due to the blood pressure lowering effects of Sacubitril and Valsartan. Symptomatic treatment should be provided. The drug is unlikely to be removed by hemodialysis because of high protein binding. \n \n

\n

Commercial Pack

\nSabitar 24/26: Each box contains 1 blister strip of 10 tablets. \nSabitar 49/51: Each box contains 1 blister strip of 10 tablets. \nSabitar 97/103: Each box contains 1 blister strip of 10 tablets. \n \n